Market Overview

J.P. Morgan Reiterates Overweight Rating on Pfizer

Share:
Related PFE
$45 Billion Thursday For M&A Shows There Are Still Plenty Of Buyers Out There
Pharma Names Under Pressure Amid Perrigo Warning
Ligand Pharma Adds Tech, Grows On Partners' Success (Investor's Business Daily)

In a report published Monday, J.P. Morgan & Co. reiterated its Overweight rating on Pfizer (NYSE: PFE).

J.P. Morgan noted, “Maintain Overweight rating. We see Pfizer offering an attractive mix of 1) inexpensive valuation (11x '13 EPS), 2) an approaching nearterm new product cycle with 3) a high FCF/dividend yield, and 4) limited earnings risk, in our view. We see Pfizer's business unit divestitures as potentially unlocking significant value and anticipate continued high levels of capital return to shareholders, including what we forecast will be $10+ billion of share repurchase in 2013.”

Pfizer closed on Friday at $24.89.

Latest Ratings for PFE

DateFirmActionFromTo
Apr 2016Goldman SachsReinstatesNeutral
Apr 2016JP MorganAssumesOverweight
Apr 2016Morgan StanleyAssumesEqual-weight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Reiteration Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!